| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2503-42 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-14546
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-7275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H10-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 |
| filingDate |
2021-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70e87ec256ad25ffb8a045da72ae71c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0b86f498cd4450ce480517b67a9bb54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eb7210bfa768ecc11e9991dce32fc6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae5fb04d70322e5b6af12394ca69eea3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1253788e90233673a344d88795e33f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ea1d37c169963a0d7423d99700d90a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9d360d56b2144e524cafc2a4dc81b75 |
| publicationDate |
2022-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022036993-A1 |
| titleOfInvention |
Pexidartinib risk evaluation and mitigation strategy (rems) |
| abstract |
The present disclosure relates generally to methods for using pexidartinib and related Risk Evaluation and Mitigation Strategy (REMS), while reducing the occurrence of hepatotoxic adverse events. |
| priorityDate |
2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |